(Q34289714)

1 August 2017

1 reference

title

The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy (English)

1 reference

1 August 2017

antibiotic resistance

1 reference

Craig WA

1

1 reference

1 August 2017

1 June 2001

1 reference

1 August 2017

1 reference

1 August 2017

95 Suppl A

1 reference

1 August 2017

S12-9; discussion S26-7

1 reference

Antimicrobial resistance issues of the future

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Pharmacokinetics and pharmacodynamics of antibiotics in otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Microbiologic efficacy of antibacterial drugs for acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Efficacy of fixed combination antibiotics versus separate components in otitis media. Effectiveness of erythromycin estrolate, triple sulfonamide, ampicillin, erythromycin estolate- triple sulfonamide, and placebo in 280 patients with acute otitis m

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Penicillin-resistant Streptococcus pneumoniae in acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Antimicrobial use for pediatric upper respiratory infections: reported practice, actual practice, and parent beliefs

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990023-X

7 January 2021

10.1016/S0954-6111(01)90023-X

Identifiers

DOI

1 reference

release_mka3thisubge7jksmutdclxljm

1 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mka3thisubge7jksmutdclxljm

24 November 2022

mapped directly with Wikidata item

PubMed ID

11419669

1 reference

PubMed ID

11419669